Form 4: Helius Medical Technologies CFO Jeffrey Mathiesen Granted 26,200 Stock Options

Helius Medical Technologies' CFO and Director, Jeffrey S. Mathiesen, was granted 26,200 stock options with an exercise price of $9.76, vesting over time.

Summary

• Jeffrey S. Mathiesen, the Chief Financial Officer and a Director of Helius Medical Technologies, Inc. (HSDT), was granted 26,200 stock options.
• The options were granted on July 2, 2025, as part of the Issuer's 2022 Equity Incentive Plan.
• Each option has an exercise price of $9.76.
• The options are set to expire on July 1, 2035.
• Fifty percent (50%) of the granted options vested immediately upon the grant date.
• The remaining 50% of the options will vest in twelve successive equal quarterly installments, with the first installment beginning on September 30, 2025, contingent upon Mr. Mathiesen's continued service to the company.

Sentiment

Score: 7

Explanation: The document reports a routine grant of stock options to a key executive, which is a common practice for executive compensation and aligns management incentives with shareholder value. It does not contain information that would significantly alter the company's financial outlook or operational status, thus indicating a neutral to slightly positive sentiment due to incentive alignment.

Positives

• The grant of stock options to CFO Jeffrey S. Mathiesen aligns his financial interests with those of shareholders, incentivizing long-term company performance and value creation.
• The immediate vesting of 50% of the options provides an immediate equity stake and serves as a retention incentive for a key executive.
• The option grant is consistent with the company's established 2022 Equity Incentive Plan, indicating a structured and transparent approach to executive compensation.

Negatives

• The potential future exercise of these stock options could lead to a minor dilution of existing shares, a common characteristic of equity compensation plans.

Risks

• The ultimate financial value of the stock options to the recipient is directly dependent on Helius Medical Technologies, Inc.'s common stock price exceeding the $9.76 exercise price in the future.
• The vesting of the remaining 50% of the options is conditional on Jeffrey S. Mathiesen's continued employment, posing a risk to the full realization of the grant if his service terminates prematurely.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The grant of 26,200 stock options to Jeffrey S. Mathiesen, who serves as a Director, CFO, and Treasurer of Helius Medical Technologies, Inc., constitutes a related party transaction under the Issuer's 2022 Equity Incentive Plan.

Stakeholder Impact

• Shareholders: Potential for minor dilution if options are exercised, but also potential for increased management alignment and motivation to improve share price.
• Employees: The grant to a key executive may signal stability and a commitment to retaining talent within the company.

Next Steps

• The remaining 50% of the stock options will continue to vest in twelve equal quarterly installments, subject to Jeffrey S. Mathiesen's continued service.

Key Dates

Keywords

Helius Medical Technologies, HSDT, Jeffrey S. Mathiesen, stock options, equity incentive plan, executive compensation, Form 4, SEC filing, CFO, director, vesting, common stock